Approvals· August 30, 2026 · 16 min read
Mounjaro's CV Claim Is Noninferiority vs Trulicity, Not Placebo Superiority
By Ran Chen#GLP-1#GIP/GLP-1#Diabetes and Obesity
Topic
GIP/GLP-1
Dual incretin therapies, tirzepatide, metabolic outcomes, coverage rules, supply constraints, and class competition.
Pipeline· June 12, 2026 · 9 min read
Retatrutide Phase 3: -28.3% body weight, 45% lose ≥30%, new UTI signal at ADA 2026
By Ran Chen#GLP-1#GIP/GLP-1#Clinical Evidence
Pricing & Access· May 31, 2026 · 12 min read
GLP-1 restart after treatment interruption: PA documentation and dosing
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs